PTT in the NIR‐II region can act as a therapeutic method for tumors and significantly induce systemic immune responses, such as the promotion of dendritic cell maturation, CD8+ T cell proliferation and infiltration, and elimination of potential metastatic lesions through abscopal effect, by integrating CuS NPs with plasmids encoding IL‐12 genes for gene transfection.[93] Tumor immunotherapy was engineered more effective using CuS surface modifications to target Cas9 ribonucleoprotein (RNP) of protein tyrosine phosphatase non‐receptor type 2 (PTPN2), resulting in PTPN2 depletion. The gene discussed is PTPN2; the disease is neoplasm.